cefalexin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antibiotics, cefalosporanic acid derivatives	571	15686-71-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: cefalexin hydrochloride cephalexin cefalexin cephacillin cephalexin anhydrous cephalexin hydrochloride cephalexin hydrate cefalexin HCl cephalexin HCl	A semisynthetic cephalosporin antibiotic with antimicrobial activity similar to that of CEPHALORIDINE or CEPHALOTHIN, but somewhat less potent. It is effective against both gram-positive and gram-negative organisms. Molecular weight: 347.39 Formula: C16H17N3O4S CLOGP: -1.84 LIPINSKI: 0 HAC: 7 HDO: 3 TPSA: 112.73 ALOGS: -3.07 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

cefalexin hydrochloride
cephalexin
cefalexin
cephacillin
cephalexin anhydrous
cephalexin hydrochloride
cephalexin hydrate
cefalexin HCl
cephalexin HCl

A semisynthetic cephalosporin antibiotic with antimicrobial activity similar to that of CEPHALORIDINE or CEPHALOTHIN, but somewhat less potent. It is effective against both gram-positive and gram-negative organisms.

Molecular weight: 347.39
Formula: C16H17N3O4S
CLOGP: -1.84
LIPINSKI: 0
HAC: 7
HDO: 3
TPSA: 112.73
ALOGS: -3.07
ROTB: 4

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
2	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	13.50 mg/mL	Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine)	91 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	192.00 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	90 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.21 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	3.90 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.85 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	0.57 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Jan. 4, 1971	FDA	SHIONOGI INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	1050.88	11.05	1127	38944	309560	63139391
Cross sensitivity reaction	214.97	11.05	72	39999	2090	63446861
Type IV hypersensitivity reaction	212.88	11.05	77	39994	2821	63446130
Loss of employment	136.82	11.05	52	40019	2192	63446759
Cellulitis	129.31	11.05	205	39866	81753	63367198
Synovitis	100.60	11.05	4	40067	186914	63262037
Pemphigus	95.39	11.05	5	40066	183721	63265230
Urinary tract discomfort	94.47	11.05	29	40042	631	63448320
Oesophageal spasm	91.55	11.05	43	40028	3080	63445871
Systemic lupus erythematosus	88.92	11.05	13	40058	208905	63240046
Hand deformity	87.22	11.05	3	40068	159454	63289497
Alveolar osteitis	85.60	11.05	29	40042	872	63448079
Urinary tract infection	82.38	11.05	358	39713	264326	63184625
Glossodynia	81.27	11.05	9	40062	178867	63270084
Oesophageal pain	78.83	11.05	41	40030	3660	63445291
Tunnel vision	77.10	11.05	29	40042	1187	63447764
Animal scratch	76.27	11.05	30	40041	1388	63447563
Infusion related reaction	75.90	11.05	30	40041	245491	63203460
Arthropathy	70.45	11.05	30	40041	234762	63214189
Pericarditis	70.16	11.05	3	40068	131576	63317375
Drug ineffective	69.84	11.05	382	39689	1044383	62404568
Bladder pain	68.34	11.05	32	40039	2276	63446675
Joint swelling	66.83	11.05	65	40006	327601	63121350
Lymphoedema	62.88	11.05	55	40016	11637	63437314
Rash maculo-papular	60.52	11.05	87	39984	31809	63417142
Bronchopulmonary aspergillosis allergic	59.81	11.05	29	40042	2229	63446722
Sinus pain	59.25	11.05	33	40038	3377	63445574
Wound complication	56.36	11.05	33	40038	3714	63445237
Ear congestion	54.32	11.05	29	40042	2730	63446221
Polymyalgia rheumatica	50.81	11.05	31	40040	3760	63445191
Wound secretion	50.04	11.05	33	40038	4581	63444370
Hepatic steatosis	49.58	11.05	75	39996	28694	63420257
Paranasal sinus discomfort	49.17	11.05	32	40039	4344	63444607
Limb injury	47.62	11.05	69	40002	25408	63423543
Cystitis	47.12	11.05	106	39965	54885	63394066
Alopecia	46.55	11.05	89	39982	337447	63111504
Treatment failure	46	11.05	35	40036	199008	63249943
Emotional distress	44.01	11.05	76	39995	32473	63416478
Toxicity to various agents	43.82	11.05	55	40016	247195	63201756
General physical health deterioration	43.33	11.05	38	40033	201364	63247587
Rash	42.47	11.05	540	39531	560331	62888620
Rheumatoid arthritis	41.40	11.05	60	40011	253759	63195192
Gastric disorder	40.12	11.05	79	39992	37290	63411661
Bronchitis	39.55	11.05	170	39901	124765	63324186
Injury	37.93	11.05	117	39954	73130	63375821
Swollen tongue	37.88	11.05	74	39997	34726	63414225
Nasal polyps	37.80	11.05	31	40040	6008	63442943
Urticaria	36.28	11.05	203	39868	165599	63283352
Opsoclonus myoclonus	36.24	11.05	10	40061	147	63448804
Cholecystitis chronic	35.42	11.05	38	40033	10323	63438628
Depression	34.99	11.05	228	39843	196264	63252687
Acute generalised exanthematous pustulosis	34.98	11.05	39	40032	11060	63437891
Hepatitis infectious mononucleosis	34.30	11.05	9	40062	108	63448843
Nephrolithiasis	33.83	11.05	79	39992	41905	63407046
Dysuria	32.28	11.05	68	40003	33670	63415281
Discomfort	32.04	11.05	35	40036	167339	63281612
Hepatic enzyme increased	31.84	11.05	49	40022	202279	63246672
Swelling face	31.58	11.05	100	39971	63375	63385576
Chronic kidney disease	30.83	11.05	80	39991	45318	63403633
Hallucination	30.68	11.05	90	39981	54727	63394224
Skin laceration	30.66	11.05	53	40018	22655	63426296
Bronchiectasis	30.57	11.05	44	40027	16098	63432853
Hypoaesthesia oral	29.93	11.05	39	40032	12994	63435957
Blood urine present	29.90	11.05	42	40029	15027	63433924
Calculus urinary	28.53	11.05	15	40056	1369	63447582
Uterine perforation	28.25	11.05	28	40043	6935	63442016
Bronchomalacia	28.21	11.05	9	40062	223	63448728
Sleep apnoea syndrome	28.20	11.05	59	40012	29074	63419877
Anxiety	28.17	11.05	234	39837	217307	63231644
Oedema	27.99	11.05	129	39942	97493	63351458
Muscle injury	27.93	11.05	4	40067	65341	63383610
Intentional product use issue	27.65	11.05	24	40047	127868	63321083
Therapeutic product effect incomplete	27.61	11.05	23	40048	125033	63323918
Diarrhoea	27.53	11.05	617	39454	714749	62734202
Contraindicated product administered	26.92	11.05	61	40010	217587	63231364
Pigment nephropathy	26.42	11.05	6	40065	37	63448914
Hypokinesia	26.41	11.05	38	40033	13898	63435053
Migraine	26.33	11.05	132	39939	103214	63345737
Dysphonia	25.53	11.05	77	39994	47537	63401414
Completed suicide	25.17	11.05	33	40038	145640	63303311
Procedural pain	24.87	11.05	47	40024	21522	63427429
Blood iron decreased	24.83	11.05	38	40033	14683	63434268
Swelling	24.66	11.05	90	39981	275288	63173663
Familial periodic paralysis	22.95	11.05	6	40065	71	63448880
Gallbladder disorder	22.90	11.05	42	40029	18800	63430151
Localised infection	22.35	11.05	55	40016	30155	63418796
Abdominal pain upper	22.07	11.05	213	39858	206231	63242720
Rales	21.73	11.05	33	40038	12664	63436287
Anaphylactic reaction	21.72	11.05	91	39980	66009	63382942
Deep vein thrombosis	21.32	11.05	107	39964	83693	63365258
Hypoacusis	21.18	11.05	47	40024	24104	63424847
Folliculitis	21.04	11.05	9	40062	70308	63378643
Agitation neonatal	20.85	11.05	9	40062	528	63448423
Pollakiuria	20.81	11.05	51	40020	27886	63421065
Wound	20.80	11.05	45	40026	163218	63285733
Cardiac failure congestive	20.75	11.05	114	39957	92319	63356632
Myopathy	20.46	11.05	30	40041	11161	63437790
Idiosyncratic drug reaction	20.04	11.05	10	40061	818	63448133
Movement disorder	19.96	11.05	43	40028	21618	63427333
Intentional overdose	19.89	11.05	11	40060	74141	63374810
Burning sensation	19.54	11.05	77	39994	54330	63394621
Haematuria	19.40	11.05	51	40020	29106	63419845
Malaise	19.29	11.05	369	39702	415585	63033366
Amniotic cavity infection	18.67	11.05	11	40060	1252	63447699
Immunoglobulins decreased	18.44	11.05	11	40060	1281	63447670
Irritable bowel syndrome	18.38	11.05	15	40056	82397	63366554
Bullous haemorrhagic dermatosis	18.28	11.05	5	40066	71	63448880
Type I hypersensitivity	18.20	11.05	15	40056	2927	63446024
Ear pain	18.05	11.05	57	40014	36061	63412890
Implant site haematoma	17.91	11.05	5	40066	77	63448874
Loss of personal independence in daily activities	17.89	11.05	21	40050	97269	63351682
Cough	17.66	11.05	271	39800	292472	63156479
Tinnitus	17.60	11.05	56	40015	35572	63413379
Mobility decreased	17.51	11.05	31	40040	121128	63327823
Product dose omission issue	17.38	11.05	225	39846	234088	63214863
Clostridium test positive	17.09	11.05	15	40056	3186	63445765
Poor feeding infant	17.04	11.05	7	40064	363	63448588
Staphylococcal infection	16.98	11.05	61	40010	41195	63407756
Panic attack	16.88	11.05	41	40030	22290	63426661
Gastrointestinal disorder	16.86	11.05	36	40035	131203	63317748
Gastroenteritis bacterial	16.86	11.05	7	40064	373	63448578
Musculoskeletal stiffness	16.74	11.05	60	40011	184558	63264393
Anhedonia	16.67	11.05	27	40044	10947	63438004
Coma	16.62	11.05	10	40061	64354	63384597
Clostridium difficile infection	16.62	11.05	49	40022	29873	63419078
Toxic epidermal necrolysis	16.54	11.05	44	40027	25290	63423661
Drug dependence	16.47	11.05	43	40028	24440	63424511
Drug ineffective for unapproved indication	16.33	11.05	53	40018	34010	63414941
Chills	16.32	11.05	125	39946	113253	63335698
Delirium	15.88	11.05	6	40065	50535	63398416
Pruritus	15.85	11.05	318	39753	361135	63087816
Fluid retention	15.74	11.05	77	39994	59609	63389342
Nasopharyngitis	15.72	11.05	95	39976	254162	63194789
Sinus disorder	15.38	11.05	42	40029	24511	63424440
C-reactive protein abnormal	15.30	11.05	5	40066	46091	63402860
Vanishing bile duct syndrome	15.28	11.05	8	40063	724	63448227
Skin infection	15.24	11.05	31	40040	14971	63433980
Drug abuse	15.20	11.05	14	40057	72504	63376447
Type 2 diabetes mellitus	15.04	11.05	11	40060	63857	63385094
Lactic acidosis	14.91	11.05	3	40068	38284	63410667
C-reactive protein increased	14.82	11.05	23	40048	94684	63354267
Complement factor C4 increased	14.71	11.05	5	40066	152	63448799
Multiple lentigines syndrome	14.67	11.05	5	40066	153	63448798
Foetal heart rate decreased	14.64	11.05	5	40066	154	63448797
Influenza	14.62	11.05	118	39953	108604	63340347
Abscess drainage	14.51	11.05	7	40064	532	63448419
Overdose	14.42	11.05	32	40039	115046	63333905
Purpura senile	14.22	11.05	7	40064	556	63448395
Joint injury	14.17	11.05	46	40025	29526	63419425
Feeling cold	14.11	11.05	40	40031	23848	63425103
Off label use	13.94	11.05	322	39749	674140	62774811
Pyelonephritis	13.83	11.05	33	40038	17745	63431206
Clostridium difficile colitis	13.71	11.05	36	40035	20533	63428418
Morbid thoughts	13.55	11.05	7	40064	616	63448335
Umbilical cord around neck	13.50	11.05	5	40066	196	63448755
Angioedema	13.46	11.05	63	40008	47902	63401049
Fall	13.36	11.05	333	39738	392001	63056950
Skin cancer	13.19	11.05	25	40046	11470	63437481
Breast abscess	13.01	11.05	10	40061	1766	63447185
Developmental hip dysplasia	12.94	11.05	9	40062	1363	63447588
Liposuction	12.88	11.05	3	40068	21	63448930
Implant site infection	12.85	11.05	8	40063	1006	63447945
Condition aggravated	12.74	11.05	178	39893	402039	63046912
Ill-defined disorder	12.66	11.05	20	40051	81735	63367216
Hidradenitis	12.59	11.05	12	40059	2834	63446117
Sleep disorder	12.58	11.05	20	40051	81546	63367405
Rhabdomyolysis	12.56	11.05	6	40065	43945	63405006
Ureteric obstruction	12.55	11.05	10	40061	1860	63447091
Appetite disorder	12.49	11.05	19	40052	7302	63441649
Retroperitoneal haematoma	12.35	11.05	12	40059	2901	63446050
Therapy non-responder	12.30	11.05	18	40053	75883	63373068
Scar	12.29	11.05	27	40044	13755	63435196
Helicobacter duodenal ulcer	12.22	11.05	3	40068	27	63448924
Maternal exposure during pregnancy	12.19	11.05	85	39986	219977	63228974
Illness	12.02	11.05	62	40009	48997	63399954
Lip swelling	12.00	11.05	45	40026	31018	63417933
Malignant neoplasm progression	11.87	11.05	21	40050	82100	63366851
Psoriatic arthropathy	11.84	11.05	25	40046	91495	63357456
Ecthyma	11.59	11.05	5	40066	293	63448658
Meconium in amniotic fluid	11.57	11.05	5	40066	294	63448657
Incorrect dose administered	11.53	11.05	71	40000	59897	63389054
Muscle haemorrhage	11.47	11.05	12	40059	3167	63445784
Wrist fracture	11.42	11.05	26	40045	13561	63435390
Vision blurred	11.41	11.05	98	39973	91826	63357125
Arthritis infective	11.32	11.05	17	40054	6461	63442490
Tarsal tunnel syndrome	11.21	11.05	6	40065	568	63448383
Dysarthria	11.19	11.05	55	40016	42656	63406295
Osteomyelitis	11.16	11.05	39	40032	25981	63422970
Full blood count decreased	11.16	11.05	39	40032	25985	63422966
Cholelithiasis	11.11	11.05	56	40015	43869	63405082
Diabetic retinal oedema	11.07	11.05	5	40066	327	63448624
Febrile neutropenia	11.06	11.05	38	40033	118411	63330540
Product odour abnormal	11.06	11.05	8	40063	1288	63447663

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	137.60	12.83	180	16429	80349	34859973
Cellulitis	89.79	12.83	118	16491	52833	34887489
Rash	74.87	12.83	254	16355	222498	34717824
Clostridium test positive	59.78	12.83	30	16579	3312	34937010
Pruritus	37.53	12.83	150	16459	141831	34798491
Clostridium difficile infection	36.55	12.83	45	16564	18853	34921469
Drug abuse	35.88	12.83	3	16606	99093	34841229
Drug interaction	33.28	12.83	35	16574	225911	34714411
Pulmonary vasculitis	33.19	12.83	12	16597	587	34939735
Venolymphatic malformation	30.47	12.83	6	16603	23	34940299
Urticaria	30.16	12.83	81	16528	62296	34878026
Autoimmune hepatitis	29.72	12.83	21	16588	4339	34935983
Localised infection	29.47	12.83	39	16570	17548	34922774
Urinary tract infection	29.10	12.83	97	16512	83984	34856338
Skin infection	28.55	12.83	26	16583	7711	34932611
Neuritis	28.02	12.83	12	16597	922	34939400
Erythema	27.74	12.83	99	16510	88681	34851641
Drug tolerance decreased	27.58	12.83	15	16594	1952	34938370
Sleep disorder due to a general medical condition	26.35	12.83	21	16588	5200	34935122
Skin laceration	26.17	12.83	31	16578	12478	34927844
Circumoral oedema	24.79	12.83	6	16603	69	34940253
Biliary sepsis	24.41	12.83	10	16599	687	34939635
Rash pruritic	24.41	12.83	45	16564	26896	34913426
Toxicity to various agents	24.30	12.83	36	16573	200326	34739996
Cross sensitivity reaction	23.41	12.83	12	16597	1385	34938937
Joint swelling	23.35	12.83	72	16537	59818	34880504
Renal hypoplasia	23.08	12.83	6	16603	94	34940228
Gut fermentation syndrome	22.95	12.83	4	16605	6	34940316
Limb injury	22.87	12.83	28	16581	11661	34928661
Clostridium difficile colitis	22.03	12.83	32	16577	15698	34924624
Stevens-Johnson syndrome	21.98	12.83	35	16574	18604	34921718
Respiratory symptom	20.57	12.83	12	16597	1785	34938537
Type IV hypersensitivity reaction	20.28	12.83	11	16598	1423	34938899
General physical health deterioration	19.85	12.83	19	16590	128250	34812072
Kounis syndrome	19.21	12.83	13	16596	2505	34937817
Skin lesion	19.04	12.83	36	16573	21925	34918397
Rheumatoid factor negative	18.86	12.83	9	16600	890	34939432
Haemorrhoids thrombosed	18.79	12.83	6	16603	200	34940122
Middle ear effusion	18.32	12.83	8	16601	644	34939678
Primary biliary cholangitis	18.27	12.83	6	16603	219	34940103
Alveolar osteitis	18.23	12.83	5	16604	97	34940225
Skin ulcer	17.53	12.83	35	16574	22181	34918141
Renal injury	17.49	12.83	24	16585	11171	34929151
Peripheral swelling	17.18	12.83	77	16532	76464	34863858
Urinary tract discomfort	17.11	12.83	5	16604	123	34940199
Lip haemorrhage	17.05	12.83	8	16601	762	34939560
Retinal degeneration	16.71	12.83	7	16602	509	34939813
Paradoxical pain	16.66	12.83	3	16606	6	34940316
Swollen tongue	16.64	12.83	27	16582	14578	34925744
Drug-induced liver injury	16.58	12.83	40	16569	28792	34911530
Skin necrosis	16.56	12.83	17	16592	5836	34934486
Tubulointerstitial nephritis	16.44	12.83	33	16576	20991	34919331
Fungal skin infection	16.38	12.83	12	16597	2622	34937700
Mucormycosis	16.35	12.83	17	16592	5925	34934397
Polyomavirus-associated nephropathy	16.35	12.83	14	16595	3830	34936492
Treatment failure	16.25	12.83	54	16555	46643	34893679
Arthropathy	16.20	12.83	38	16571	26869	34913453
Hypersensitivity vasculitis	15.95	12.83	13	16596	3322	34937000
Perineal abscess	15.50	12.83	6	16603	355	34939967
Factor V inhibition	14.99	12.83	5	16604	192	34940130
Neovascular age-related macular degeneration	14.74	12.83	5	16604	202	34940120
Skin cancer	14.49	12.83	21	16588	10276	34930046
Urethral injury	14.33	12.83	4	16605	83	34940239
Animal scratch	14.21	12.83	5	16604	226	34940096
Renal tubular necrosis	13.96	12.83	26	16583	15654	34924668
Swelling	13.87	12.83	48	16561	42318	34898004
Therapy interrupted	13.84	12.83	24	16585	13673	34926649
Allergy test positive	13.82	12.83	4	16605	95	34940227
Reversible airways obstruction	13.74	12.83	6	16603	483	34939839
Angioedema	13.70	12.83	44	16565	37330	34902992
Herpes simplex	13.70	12.83	15	16594	5544	34934778
Neurological symptom	13.40	12.83	13	16596	4172	34936150
Acute hepatic failure	13.37	12.83	24	16585	14050	34926272
Pyogenic granuloma	13.28	12.83	5	16604	274	34940048
Mean platelet volume increased	13.28	12.83	6	16603	524	34939798
Multiple allergies	12.90	12.83	11	16598	2992	34937330

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	784.76	10.70	915	45442	298001	79400030
Type IV hypersensitivity reaction	232.44	10.70	88	46269	3993	79694038
Cross sensitivity reaction	225.81	10.70	84	46273	3628	79694403
Cellulitis	170.74	10.70	260	46097	108800	79589231
Loss of employment	130.24	10.70	51	46306	2536	79695495
Rash	107.26	10.70	637	45720	577721	79120310
Oesophageal spasm	96.93	10.70	45	46312	3411	79694620
Oesophageal pain	90.71	10.70	46	46311	4233	79693798
Urinary tract discomfort	85.17	10.70	27	46330	714	79697317
Urinary tract infection	83.29	10.70	348	46009	274164	79423867
Alveolar osteitis	81.68	10.70	27	46330	818	79697213
Animal scratch	70.49	10.70	28	46329	1446	79696585
Synovitis	68.38	10.70	5	46352	150729	79547302
Clostridium test positive	68.10	10.70	44	46313	6410	79691621
Toxicity to various agents	67.19	10.70	88	46269	421452	79276579
Tunnel vision	65.24	10.70	27	46330	1551	79696480
Bladder pain	64.21	10.70	30	46327	2307	79695724
Lymphoedema	63.95	10.70	55	46302	12358	79685673
Urticaria	62.68	10.70	243	46114	184958	79513073
Rash maculo-papular	60.14	10.70	113	46244	55965	79642066
Drug abuse	57.88	10.70	12	46345	162679	79535352
Swollen tongue	57.59	10.70	95	46262	42475	79655556
Limb injury	57.28	10.70	78	46279	29450	79668581
Sinus pain	53.55	10.70	31	46326	3711	79694320
Infusion related reaction	52.00	10.70	35	46322	230202	79467829
General physical health deterioration	50.82	10.70	51	46306	275187	79422844
Ear congestion	49.41	10.70	27	46330	2892	79695139
Pericarditis	48.61	10.70	3	46354	104233	79593798
Clostridium difficile infection	48.26	10.70	88	46269	42597	79655434
Bronchopulmonary aspergillosis allergic	48.21	10.70	27	46330	3034	79694997
Cystitis	46.60	10.70	98	46259	52634	79645397
Bronchitis	46.30	10.70	174	46183	130470	79567561
Paranasal sinus discomfort	46.08	10.70	30	46327	4426	79693605
Wound secretion	45.98	10.70	34	46323	6154	79691877
Hand deformity	45.59	10.70	4	46353	103915	79594116
Wound complication	45.33	10.70	31	46326	4962	79693069
Skin laceration	45.20	10.70	69	46288	28893	79669138
Pruritus	45.04	10.70	387	45970	394261	79303770
Polymyalgia rheumatica	43.17	10.70	29	46328	4508	79693523
Systemic lupus erythematosus	39.04	10.70	11	46346	121138	79576893
Pemphigus	38.32	10.70	6	46351	99576	79598455
Oedema	38.09	10.70	154	46203	119426	79578605
Swelling face	37.97	10.70	109	46248	71103	79626928
Acute generalised exanthematous pustulosis	37.20	10.70	48	46309	17206	79680825
Emotional distress	36.15	10.70	75	46282	39894	79658137
Cholecystitis chronic	35.75	10.70	36	46321	9870	79688161
Nasal polyps	34.80	10.70	31	46326	7296	79690735
Gastric disorder	34.75	10.70	71	46286	37362	79660669
Injury	34.19	10.70	111	46246	77385	79620646
Sleep apnoea syndrome	33.64	10.70	69	46288	36409	79661622
Opsoclonus myoclonus	33.20	10.70	10	46347	222	79697809
Migraine	33.06	10.70	119	46238	87374	79610657
Uterine perforation	32.61	10.70	28	46329	6275	79691756
Hepatitis infectious mononucleosis	32.36	10.70	9	46348	149	79697882
Skin infection	30.65	10.70	45	46312	18200	79679831
Localised infection	29.96	10.70	67	46290	37508	79660523
Drug interaction	29.22	10.70	133	46224	415050	79282981
Glossodynia	28.77	10.70	12	46345	103325	79594706
Hepatic steatosis	28.65	10.70	66	46291	37672	79660359
Completed suicide	28.35	10.70	63	46294	245704	79452327
Drug ineffective	28.13	10.70	451	45906	1080462	78617569
Pulmonary vasculitis	28.05	10.70	12	46345	749	79697282
Nephrolithiasis	27.86	10.70	81	46276	53210	79644821
Depression	27.58	10.70	218	46139	216572	79481459
Anxiety	26.90	10.70	241	46116	248271	79449760
Anaphylactic reaction	26.78	10.70	108	46249	83635	79614396
Angioedema	26.70	10.70	101	46256	75934	79622097
Intentional product use issue	26.03	10.70	30	46327	152082	79545949
Pigment nephropathy	25.66	10.70	6	46351	47	79697984
Hypoaesthesia oral	25.43	10.70	36	46321	14088	79683943
Lactic acidosis	25.41	10.70	5	46352	70354	79627677
Diarrhoea	25.32	10.70	680	45677	879809	78818222
Chronic kidney disease	25.01	10.70	90	46267	66064	79631967
Hepatic function abnormal	24.77	10.70	6	46351	73101	79624930
Calculus urinary	24.07	10.70	16	46341	2444	79695587
Clostridium difficile colitis	24.01	10.70	56	46301	32227	79665804
Thrombocytopenia	23.79	10.70	77	46280	265182	79432849
Gallbladder disorder	23.30	10.70	41	46316	19299	79678732
Alopecia	22.28	10.70	65	46292	231290	79466741
Coma	21.78	10.70	16	46341	100633	79597398
Pollakiuria	21.74	10.70	59	46298	37258	79660773
Blood urine present	21.70	10.70	42	46315	21255	79676776
Procedural pain	21.68	10.70	44	46313	23040	79674991
Type I hypersensitivity	21.67	10.70	19	46338	4379	79693652
Deep vein thrombosis	21.51	10.70	132	46225	120787	79577244
Erythema	21.39	10.70	211	46146	223079	79474952
Gut fermentation syndrome	21.09	10.70	4	46353	9	79698022
Febrile neutropenia	20.75	10.70	67	46290	230932	79467099
Neutropenia	20.32	10.70	92	46265	287618	79410413
Rhabdomyolysis	20.31	10.70	18	46339	103113	79594918
Blood iron decreased	20.28	10.70	34	46323	15400	79682631
Ear pain	20.19	10.70	53	46304	32816	79665215
Stevens-Johnson syndrome	19.96	10.70	59	46298	39107	79658924
Off label use	19.59	10.70	391	45966	906824	78791207
Anaemia	19.59	10.70	165	46192	444850	79253181
Dysphonia	19.52	10.70	75	46282	56797	79641234
Intentional overdose	19.12	10.70	20	46337	105940	79592091
Tinnitus	19.10	10.70	63	46294	44270	79653761
Implant site haematoma	18.70	10.70	6	46351	165	79697866
Hypokinesia	18.70	10.70	37	46320	19023	79679008
Neuritis	18.58	10.70	12	46345	1746	79696285
Familial periodic paralysis	18.57	10.70	6	46351	169	79697862
Autoimmune hepatitis	18.28	10.70	28	46329	11755	79686276
Skin cancer	18.27	10.70	32	46325	15008	79683023
Burning sensation	18.25	10.70	75	46282	58557	79639474
Dysuria	18.15	10.70	68	46289	50883	79647148
Genital ulceration	18.14	10.70	10	46347	1090	79696941
Panic attack	18.00	10.70	42	46315	24174	79673857
Bronchiectasis	17.94	10.70	40	46317	22346	79675685
Pemphigoid	17.85	10.70	32	46325	15283	79682748
Sinus disorder	17.84	10.70	40	46317	22424	79675607
Middle ear effusion	17.34	10.70	13	46344	2402	79695629
Bullous haemorrhagic dermatosis	17.33	10.70	5	46352	95	79697936
Surgery	17.31	10.70	50	46307	32716	79665315
Hypoacusis	16.90	10.70	47	46310	30103	79667928
Drug reaction with eosinophilia and systemic symptoms	16.81	10.70	78	46279	64166	79633865
Lip swelling	16.62	10.70	57	46300	40854	79657177
Therapeutic product effect incomplete	16.58	10.70	36	46321	141609	79556422
Haemorrhoids thrombosed	16.40	10.70	6	46351	247	79697784
Drug-induced liver injury	16.37	10.70	79	46278	66038	79631993
Gastroenteritis bacterial	16.29	10.70	7	46350	442	79697589
Product odour abnormal	16.28	10.70	10	46347	1334	79696697
Product dose omission issue	16.10	10.70	217	46140	247320	79450711
Skin ulcer	15.87	10.70	68	46289	54082	79643949
Abdominal pain upper	15.30	10.70	198	46159	223621	79474410
Tarsal tunnel syndrome	15.10	10.70	7	46350	529	79697502
Cardiogenic shock	15.09	10.70	3	46354	41911	79656120
Circumoral oedema	15.01	10.70	6	46351	315	79697716
Therapy cessation	14.97	10.70	52	46305	37510	79660521
Fungal skin infection	14.94	10.70	18	46339	6018	79692013
Complement factor C4 increased	14.92	10.70	5	46352	158	79697873
Hallucination	14.87	10.70	93	46264	85652	79612379
Movement disorder	14.79	10.70	42	46315	27217	79670814
Arthropathy	14.79	10.70	53	46304	177058	79520973
Biliary sepsis	14.59	10.70	10	46347	1607	79696424
Rash pruritic	14.55	10.70	81	46276	71548	79626483
Paradoxical pain	14.53	10.70	3	46354	12	79698019
Tubulointerstitial nephritis	14.43	10.70	52	46305	38183	79659848
Oral pain	14.43	10.70	46	46311	31752	79666279
Diabetic retinal oedema	14.36	10.70	6	46351	353	79697678
Appetite disorder	14.34	10.70	20	46337	7719	79690312
Haematuria	14.09	10.70	78	46279	68758	79629273
Multiple lentigines syndrome	13.92	10.70	5	46352	195	79697836
Toxic epidermal necrolysis	13.85	10.70	57	46300	44524	79653507
Abscess drainage	13.77	10.70	7	46350	647	79697384
Multiple organ dysfunction syndrome	13.71	10.70	31	46326	120215	79577816
Idiosyncratic drug reaction	13.70	10.70	9	46348	1348	79696683
Actinic keratosis	13.32	10.70	17	46340	6025	79692006
Arthritis infective	13.32	10.70	20	46337	8251	79689780
Chills	13.25	10.70	147	46210	160087	79537944
Malignant neoplasm progression	13.24	10.70	38	46319	135952	79562079
Hepatic enzyme increased	13.12	10.70	58	46299	182552	79515479
Discomfort	13.05	10.70	34	46323	125583	79572448
Fluid retention	12.91	10.70	77	46280	69732	79628299
C-reactive protein abnormal	12.85	10.70	6	46351	48361	79649670
Hidradenitis	12.74	10.70	12	46345	3032	79694999
Kounis syndrome	12.67	10.70	14	46343	4268	79693763
Blood creatine phosphokinase increased	12.46	10.70	12	46345	66078	79631953
Morbid thoughts	12.43	10.70	7	46350	795	79697236
Rheumatoid factor negative	12.38	10.70	8	46349	1165	79696866
Helicobacter duodenal ulcer	12.27	10.70	3	46354	29	79698002
Lip haemorrhage	12.25	10.70	8	46349	1186	79696845
Tinea infection	12.18	10.70	8	46349	1197	79696834
Joint injury	12.16	10.70	43	46314	31292	79666739
Purpura senile	12.12	10.70	6	46351	524	79697507
Skin induration	12.04	10.70	14	46343	4511	79693520
Vulvovaginal mycotic infection	11.94	10.70	14	46343	4552	79693479
Ureteric obstruction	11.93	10.70	11	46346	2705	79695326
Staphylococcal infection	11.89	10.70	66	46291	58229	79639802
Drug ineffective for unapproved indication	11.82	10.70	60	46297	51178	79646853
Sleep disorder	11.57	10.70	20	46337	85657	79612374
Wrist fracture	11.53	10.70	23	46334	11898	79686133
Vanishing bile duct syndrome	11.51	10.70	9	46348	1769	79696262
Agranulocytosis	11.34	10.70	6	46351	45024	79653007
Hepatotoxicity	11.32	10.70	8	46349	51344	79646687
Interstitial lung disease	11.30	10.70	31	46326	112569	79585462
Gastrointestinal disorder	11.28	10.70	35	46322	122170	79575861
Bone marrow failure	11.22	10.70	8	46349	51099	79646932
Renal tubular necrosis	11.16	10.70	36	46321	25003	79673028
Renal injury	11.13	10.70	28	46329	16899	79681132
Back pain	11.12	10.70	243	46114	303937	79394094
Polyomavirus-associated nephropathy	11.12	10.70	15	46342	5612	79692419
Pancytopenia	11.10	10.70	54	46303	165691	79532340
Illness	11.10	10.70	55	46302	46456	79651575
Drug dependence	11.04	10.70	50	46307	40719	79657312
Factor V inhibition	10.81	10.70	5	46352	376	79697655
Breast abscess	10.77	10.70	8	46349	1458	79696573

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J01DB01	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS First-generation cephalosporins
FDA CS	M0003827	Cephalosporins
FDA EPC	N0000175488	Cephalosporin Antibacterial
CHEBI has role	CHEBI:36047	antibacterial drugs
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Acute otitis media	indication	3110003
Prostatitis	indication	9713002	DOID:14654
Haemophilus Influenzae Acute Otitis Media	indication	19021002
Infection of skin AND/OR subcutaneous tissue	indication	19824006
Pneumonia due to Streptococcus	indication	34020007
Streptococcal tonsillitis	indication	41582007
Klebsiella cystitis	indication	60867007
Infection of bone	indication	111253001
Escherichia coli urinary tract infection	indication	301011002
Proteus urinary tract infection	indication	301012009
Streptococcus pyogenes infection	indication	302809008
Bacterial urinary infection	indication	312124009
Infective otitis media	indication	312218008
Infectious disorder of joint	indication	363162000
Infection due to Staphylococcus aureus	indication	406602003
Osteomyelitis due to Staphylococcus aureus	indication	428783003
Staphylococcus Acute Otitis Media	indication	703469002
Moraxella Catarrhalis Acute Otitis Media	indication	703469002
Klebsiella Prostatitis	indication
Proteus Prostatitis	indication
Streptococcus Osteomyelitis	indication
Bacterial Mastitis	off-label use
Prevention of Bacterial Endocarditis	off-label use
Diabetic Foot Infection Due to Gram-Positive Bacteria	off-label use
Colitis	contraindication	64226004	DOID:0060180
Kidney disease	contraindication	90708001	DOID:557
Pseudomembranous enterocolitis	contraindication	397683000

🐶 Veterinary Drug Use

Species	Use	Relation
Dogs	Secondary superficial bacterial pyoderma caused by Staphylococcus pseudintermedius	Indication

🐶 Veterinary products

Product	Applicant	Ingredients
Rilexine Chewable Tablets	Virbac AH Inc.	1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.77	acidic
pKa2	13.53	acidic
pKa3	7.67	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Solute carrier family 15 member 2	Transporter	Q16348	S15A2_HUMAN		IC50	4.38	WOMBAT-PK
Bacterial penicillin-binding protein	Enzyme		PBPA_ECOLI PBPB_ECOLI DACC_ECOLI PBP2_ECOLI FTSI_ECOLI DACA_ECOLI DACB_ECOLI	INHIBITOR			CHEMBL	CHEMBL
Penicillin-binding protein 3	Enzyme		PBPC_BACSU				WOMBAT-PK

External reference:

ID	Source
4018893	VUID
N0000179741	NUI
D00263	KEGG_DRUG
23325-78-2	SECONDARY_CAS_RN
1299782	RXNORM
C0007716	UMLSCUI
CHEBI:3534	CHEBI
CHEMBL1727	ChEMBL_ID
CHEMBL1200544	ChEMBL_ID
CHEMBL1200366	ChEMBL_ID
DB00567	DRUGBANK_ID
4832	IUPHAR_LIGAND_ID
105879-42-3	SECONDARY_CAS_RN
27447	PUBCHEM_CID
4393	MMSL
d00096	MMSL
002716	NDDF
002717	NDDF
387304003	SNOMEDCT_US
54062005	SNOMEDCT_US
54887004	SNOMEDCT_US
785690001	SNOMEDCT_US
D002506	MESH_DESCRIPTOR_UI
4018891	VANDF
4018893	VANDF
2400	INN_ID
OBN7UDS42Y	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-2238	TABLET	250 mg	ORAL	ANDA	19 sections
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-2238	TABLET	250 mg	ORAL	ANDA	19 sections
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-2240	TABLET	500 mg	ORAL	ANDA	19 sections
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-2240	TABLET	500 mg	ORAL	ANDA	19 sections
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-3145	CAPSULE	250 mg	ORAL	ANDA	23 sections
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-3145	CAPSULE	250 mg	ORAL	ANDA	23 sections
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-3147	CAPSULE	500 mg	ORAL	ANDA	23 sections
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-3147	CAPSULE	500 mg	ORAL	ANDA	23 sections
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-4175	POWDER, FOR SUSPENSION	125 mg	ORAL	ANDA	23 sections
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-4175	POWDER, FOR SUSPENSION	125 mg	ORAL	ANDA	23 sections
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-4177	POWDER, FOR SUSPENSION	250 mg	ORAL	ANDA	23 sections
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-4177	POWDER, FOR SUSPENSION	250 mg	ORAL	ANDA	23 sections
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9769	SUSPENSION	125 mg	ORAL	ANDA	24 sections
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9770	SUSPENSION	250 mg	ORAL	ANDA	24 sections
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9897	CAPSULE	500 mg	ORAL	ANDA	23 sections
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9898	CAPSULE	250 mg	ORAL	ANDA	23 sections
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	0440-1243	CAPSULE	250 mg	ORAL	ANDA	19 sections
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	0440-7244	CAPSULE	500 mg	ORAL	ANDA	23 sections
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	10544-004	CAPSULE	500 mg	ORAL	ANDA	23 sections
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	10544-013	CAPSULE	500 mg	ORAL	ANDA	24 sections
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	10544-020	CAPSULE	500 mg	ORAL	ANDA	23 sections
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	10544-021	CAPSULE	250 mg	ORAL	ANDA	24 sections
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	10544-025	CAPSULE	500 mg	ORAL	ANDA	24 sections
cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	10544-057	CAPSULE	500 mg	ORAL	ANDA	24 sections
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	10544-066	CAPSULE	250 mg	ORAL	ANDA	19 sections
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	10544-082	CAPSULE	500 mg	ORAL	ANDA	21 sections
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	10544-142	CAPSULE	250 mg	ORAL	ANDA	23 sections
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	10544-503	CAPSULE	500 mg	ORAL	ANDA	13 sections
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	10544-529	CAPSULE	500 mg	ORAL	ANDA	22 sections
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	10544-617	CAPSULE	500 mg	ORAL	ANDA	19 sections